Related Experiment Video
Updated: Aug 9, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Intermediate biomarkers in the colorectal tumor progression
1Centro Ricerche Neoplasie Apparato Digerente L. Novello Miglino, Ospedale San Giovanni Antica Sede, Torino, Italy.
Tumori
|May 1, 1995
Summary
Cell proliferation and DNA aneuploidy serve as key intermediate biomarkers for monitoring colorectal tumor progression. Understanding these markers aids in assessing malignant transformation risk and planning lesion regression strategies.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Intermediate biomarkers signal carcinogenesis stages between tumor initiation and malignancy.
- Cell proliferation changes in intestinal mucosa are early events in colorectal neoplasia.
- Proliferation biomarkers are crucial for monitoring colorectal tumor progression.
Purpose of the Study:
- To highlight the significance of proliferation biomarkers in colorectal carcinogenesis.
- To emphasize the role of differentiation and genomic markers in monitoring tumor progression.
- To identify DNA aneuploidy as an indicator of malignant transformation risk in colorectal adenomas.
Main Methods:
- Analysis of cell proliferation in histologically normal intestinal mucosa.
- Utilizing differentiation and genomic markers to monitor tumor progression.
- Assessing the incidence and degree of DNA aneuploidy in colorectal adenomas.
Main Results:
- Cell proliferation changes are early events closely associated with colorectal neoplasia morphogenesis.
- Differentiation and genomic markers reliably monitor colorectal tumor progression.
- DNA aneuploidy incidence and degree indicate malignant transformation risk in colorectal adenomas.
Conclusions:
- Proliferation biomarkers are essential for intermediate markers in colorectal tumor progression.
- Monitoring colorectal neoplasia progression is achievable using differentiation and genomic markers.
- Further investigation into "regression-related" biomarkers is needed for premalignant lesion management.
